| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| ORVILLE JACOB A | EVP, GM, Screening | C/O EXACT SCIENCES CORP., 5505 ENDEAVOR LANE, MADISON | /s/ Jacob A. Orville by Mark Busch, attorney-in-fact | 30 Dec 2025 | 0001263312 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EXAS | Common Stock | Options Exercise | $0 | +3,955 | +17% | $0.000000 | 27,192 | 23 Dec 2025 | Direct | F1 |
| transaction | EXAS | Common Stock | Tax liability | $189,283 | -1,859 | -6.8% | $101.82 | 25,333 | 23 Dec 2025 | Direct | F2 |
| transaction | EXAS | Common Stock | Options Exercise | $0 | +9,450 | +37% | $0.000000 | 34,783 | 23 Dec 2025 | Direct | F1 |
| transaction | EXAS | Common Stock | Tax liability | $452,284 | -4,442 | -13% | $101.82 | 30,341 | 23 Dec 2025 | Direct | F2 |
| transaction | EXAS | Common Stock | Options Exercise | $0 | +14,845 | +49% | $0.000000 | 45,186 | 23 Dec 2025 | Direct | F1 |
| transaction | EXAS | Common Stock | Tax liability | $710,500 | -6,978 | -15% | $101.82 | 38,208 | 23 Dec 2025 | Direct | F2 |
| transaction | EXAS | Common Stock | Options Exercise | $0 | +28,779 | +75% | $0.000000 | 66,987 | 23 Dec 2025 | Direct | F1 |
| transaction | EXAS | Common Stock | Tax liability | $1,377,319 | -13,527 | -20% | $101.82 | 53,460 | 23 Dec 2025 | Direct | F2 |
| transaction | EXAS | Common Stock | Options Exercise | $0 | +16,051 | +30% | $0.000000 | 69,511 | 23 Dec 2025 | Direct | F1 |
| transaction | EXAS | Common Stock | Tax liability | $768,130 | -7,544 | -11% | $101.82 | 61,967 | 23 Dec 2025 | Direct | F2 |
| transaction | EXAS | Common Stock | Award | $0 | +42,523 | +69% | $0.000000 | 104,490 | 23 Dec 2025 | Direct | F3 |
| transaction | EXAS | Common Stock | Tax liability | $2,034,975 | -19,986 | -19% | $101.82 | 84,504 | 23 Dec 2025 | Direct | F4 |
| transaction | EXAS | Common Stock | Award | $0 | +20,584 | +24% | $0.000000 | 105,088 | 23 Dec 2025 | Direct | F5 |
| transaction | EXAS | Common Stock | Tax liability | $985,108 | -9,675 | -9.2% | $101.82 | 95,413 | 23 Dec 2025 | Direct | F4 |
| transaction | EXAS | Common Stock | Award | $0 | +9,416 | +9.9% | $0.000000 | 104,829 | 23 Dec 2025 | Direct | F6 |
| transaction | EXAS | Common Stock | Tax liability | $450,655 | -4,426 | -4.2% | $101.82 | 100,403 | 23 Dec 2025 | Direct | F4, F7 |
| holding | EXAS | Common Stock | 1,490 | 23 Dec 2025 | Held in 401(k) Plan |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | EXAS | Restricted Stock Units | Options Exercise | $0 | -3,955 | -100% | $0.000000 | 0 | 23 Dec 2025 | Common Stock | 3,955 | Direct | F8, F9 | |
| transaction | EXAS | Restricted Stock Units | Options Exercise | $0 | -9,450 | -100% | $0.000000 | 0 | 23 Dec 2025 | Common Stock | 9,450 | Direct | F8, F10 | |
| transaction | EXAS | Restricted Stock Units | Options Exercise | $0 | -14,845 | -100% | $0.000000 | 0 | 23 Dec 2025 | Common Stock | 14,845 | Direct | F8, F11 | |
| transaction | EXAS | Restricted Stock Units | Options Exercise | $0 | -28,779 | -100% | $0.000000 | 0 | 23 Dec 2025 | Common Stock | 28,779 | Direct | F8, F12 | |
| transaction | EXAS | Restricted Stock Units | Options Exercise | $0 | -16,051 | -100% | $0.000000 | 0 | 23 Dec 2025 | Common Stock | 16,051 | Direct | F9, F13 |
| Id | Content |
|---|---|
| F1 | Represents shares of common stock received upon vesting of a restricted stock unit award. |
| F2 | Represents shares of Common Stock retained by Exact Sciences Corporation (the "Issuer") for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain restricted stock units. |
| F3 | Represents performance-based restricted share units granted to the reporting person on February 24, 2023 and that were scheduled to vest or be forfeited based on the attainment of performance-based vesting conditions during the performance period ending on December 31, 2025. The vesting of the portion reflected herein was accelerated in order to mitigate the potential impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, on the Issuer and certain of its employees in connection with the pending transactions contemplated by the Agreement and Plan of Merger, dated November 19, 2025, by and among the Issuer, Abbott Laboratories, and Badger Merger Sub I, Inc. (the "Section 280G Mitigation"). |
| F4 | Represents shares of Common Stock retained by the Issuer for tax withholding purposes in connection with the net-settlement on the issuance of shares of Common Stock in respect to the vesting of certain performance based restricted stock units. |
| F5 | Represents performance-based restricted share units granted to the reporting person on February 26, 2024 and that were scheduled to vest or be forfeited based on the attainment of performance-based vesting conditions during the performance period ending on December 31, 2026. The vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. |
| F6 | Represents performance-based restricted share units granted to the reporting person on February 24, 2025 and that were scheduled to vest or be forfeited based on the attainment of performance-based vesting conditions during the performance period ending on December 31, 2027. The vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. |
| F7 | In addition to the shares of Common Stock reported on this Form 4, which total 101,893 shares, Mr. Orville also holds, in the aggregate, an additional 6581 vested and unvested options to purchase shares of Common Stock. |
| F8 | Each restricted stock unit represents a contingent right to receive one share of common stock. |
| F9 | This award was scheduled to vest on February 25, 2026, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. |
| F10 | This award was scheduled to vest in two equal installments on February 27, 2026 and February 26, 2027, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. |
| F11 | This award was scheduled to vest in three equal installments on February 27, 2026, February 26, 2027, and February 29, 2028, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. |
| F12 | This award was scheduled to vest in four equal installments on February 27, 2026, February 26, 2027, February 29, 2028, and February 28, 2029, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. |
| F13 | This award was scheduled to vest in three equal installments on August 5, 2026, August 5, 2027, and August 5, 2028, subject to the Reporting Person's continued service through such vesting date but the vesting of the portion reflected herein was accelerated in connection with the Section 280G Mitigation. |